secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2026-07-31T00:02:23+00:00
Accession:  0001104659-26-088857
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune's RP1 gets favorable FDA advisory committee vote 10-3 for advanced melanoma
--------------------------------------------------------------------------------

- FDA advisory committee voted 10 to 3 that efficacy results from IGNYTE study are evaluable and clinically meaningful.
- RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma after anti-PD-1 progression.
- FDA target action date for BLA resubmission is August 2, 2026.
- CEO Sushil Patel expressed gratitude and looks forward to working with FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926088857/0001104659-26-088857-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465926088857/tm2621708d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-088857

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer